Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Cytosorbents Announces The Regulatory Approval Of Cytosorb In Taiwan For Extracorporeal Removal Of Cytokines (e.g. Cytokine Storm, Sepsis), Bilirubin (e.g. Liver Disease), And Myoglobin (e.g. Trauma) From A Patient's Circulating Blood

Author: Benzinga Newsdesk | June 24, 2024 07:19am

The removal of the antithrombotic drugs Brilinta® (ticagrelor, AstraZeneca) and Xarelto® (rivaroxaban, Janssen/Bayer) during cardiothoracic surgery is also approved, with the goal of reducing perioperative bleeding. CytoSorb will be distributed throughout Taiwan by Hemoscien Corporation.

Posted In: CTSO